You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Introducing Relvar Ellipta  

Relvar Ellipta is an ICS/LABA combination for the treatment of asthma and COPD [1] [2]. Relvar is the only ICS/LABA which is one inhalation, once daily, due to its unique component combination which delivers 24 hours of continuous efficacy.

The Asthma Control Test (ACT) is now available online and allows you to review your patients asthma control using a simple five question tool.

ACT Available Here

Knowledge Base

Watch webinars and videos, featuring experts in the respiratory field.

Find out more


  1. Relvar Ellipta 92/22 mcg SmPC; GlaxoSmithKline 2015
  2. Relvar Ellipta 184/22 mcg SmPC; GlaxoSmithKline 2015
  3. Valotis A & Hogger P. Human receptor kinetics and lung tissue retention of the enhanced – affinity glucocorticoid fluticasone furoate. Resp Res. 2007; 8:54.
  4. Woodcock A et al. Fluticasone furoate: once-daily evening treatment versus twice – daily treatment in moderate asthma. Resp Res. 2011; 12(1): 160.
  5. Slack RJ et al. In vitro pharmalogical characterisation of vilanterol, a novel long-acting Beta-adrenocepter agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013; 344: 218 – 230.
  6. Bernstein DI et al. Fluticasone furoate (FF)/vilanterol (100/25 mcg) or FF (100 mcg) in persistent asthma. J Asthma. 2015; 52 (10): 1073 – 1083.
Theravance logo

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Relvar and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies